Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.85 |
| ▸ | ALPI | P09923 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.85 |
| ▸ | XIAP | P98170 | 1/20 | 0.85 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.55 |
| ▸ | NOS1 | P29475 | 1/20 | 0.55 |
| ▸ | NOS2 | P35228 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL9226754 | 1.00 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28229442 | 1.00 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL6535507 | 1.00 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL8910300 | 1.00 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL37367 | 1.00 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL2063249 | 1.00 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL6033327 | 1.00 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28667668 | 0.93 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL3057091 | 0.93 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL17103846 | 0.93 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115896059-A | Cyclodextrin glycosyltransferase mutant for preparing rebaudioside RM, coding gene and application thereof | 三元生物工程研究(天津)有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-113195487-A | 2, 3-diaminosuccinyl conjugate linkers | 杭州多禧生物科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| US-10544218-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2020-01-28 | — | — | US | claimed |
| US-10292961-B2 | Disulfur bridge linkers for conjugation of a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2019-05-21 | — | — | US | claimed |
| CN-108660147-A | Method for driving expression and purification of lactoferricin by HU protein | 戚智青 | 2018-10-16 | — | — | CN | claimed |
| US-20130078732-A1 | METHODS FOR DIAGNOSING IMPENDING JOINT FAILURE | GUFFEY WENDELL RAY (US) | 2013-03-28 | — | — | US | claimed |
| EP-2391889-A2 | METHODS FOR DIAGNOSING IMPENDING JOINT FAILURE | Nestec S.A. (CH) | 2011-12-07 | — | — | EP | claimed |
| WO-2010087991-A2 | METHODS FOR DIAGNOSING IMPENDING JOINT FAILURE | NESTEC S.A. (CH) | 2010-08-05 | — | — | WO | claimed |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. | 2010-02-18 | — | — | US | claimed |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | claimed |
| WO-2007030706-A1 | FRAGMENTS OF THE GLUCAGON-LIKE PEPTIDE-I AND USES THEREOF | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2007-03-15 | — | — | WO | claimed |
| EP-4087543-B1 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | TYNDALL FORMULATION SERVICES LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117551032-A | Drug conjugates comprising quinoline derivatives | 国家科学研究中心 | 2024-02-13 | — | — | CN | disclosed |
| US-11891482-B2 | Polymer excipients for drug delivery applications | Tyndall Formulation Services, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-11844816-B2 | Compositions and methods for augmenting the nasal microbiome | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2023-12-19 | — | — | US | disclosed |
| EP-1572991-A2 | COMPOSITIONS AND METHODS FOR HYDROXILATING EPOTHILONES | Bristol-Myers Squibb Company (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1465908-A2 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004078978-A1 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004061116-A2 | COMPOSITIONS AND METHODS FOR HYDROXILATING EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2003057830-A2 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10292961-B2 | Disulfur bridge linkers for conjugation of a cell-binding molecule | CD74, CD2, EPCAM | SLC7A5 1181/4885ALPI 4041/4885PKM 4357/4885 |
| US-10544218-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | CD99, CD79B, CD47 | SLC7A5 3420/4885ALPI 2702/4885PKM 4738/4885 |
| US-11891482-B2 | Polymer excipients for drug delivery applications | CLTB, ACTB, TNNC1 | SLC7A5 20/4885ALPI 1545/4885PKM 272/4885 |
| US-20090105134-A1 | C-Terminally Pegylated Growth Hormones | GHRHR, GHITM, HDGF | SLC7A5 1160/4885ALPI 2242/4885PKM 4447/4885 |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | GLP1R, IAPP, GIPR | SLC7A5 4416/4885ALPI 1589/4885PKM 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.